Insulin Degludec
Cat# : THP-0125
| Cat#: |
THP-0125 |
| Product Name: |
Insulin Degludec |
| Description: |
The product is an ultra-long-acting insulin. Compared to endogenous insulin, this product has an added hexadecanedioic acid to lysine at the B29 position which allows for the formation of multi-hexamers. |
| Sequences: |
>A Chain
GIVEQCCTSICSLYQLENYCN
>B Chain
FVNQHLCGSHLVEALYLVCGERGFFYTPK |
| Molecular Weight: |
6103.97 Da |
| Cas No: |
844439-96-9 |
| Formula: |
C274H411N65O81S6 |
| Endotoxin Level: |
<0.1 EU per 1 μg of the protein by the LAL method |
| Biological Activity: |
200 U/ml |
| Drug Name: |
Insulin Degludec |
| Applications: |
The product is indicated to improve glycemic control in adults with diabetes mellitus. |
| Examples of Clinical Use: |
Diabetes mellitus |
| Pharmacodynamics: |
Not Available |
| Mechanism of action: |
Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake and by preventing hepatic glucose production. Compared to endogenous insulin, Insulin Degludec has an added hexadecanedioic acid to lysine at the B29 position which allows for the formation of multi-hexamers in subcutaneous tissues. When injected subcutaneously, these multi-hexamers form a drug depot store that slowly release. As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation |
| Affected organisms: |
Not Available |
| Targets: |
Target 1. Insulin receptor |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
